Literature DB >> 32388616

Exercise prescription for symptoms and quality of life improvements in lung cancer patients: a systematic review.

Alberto Codima1, Willian das Neves Silva1,2, Ana Paula de Souza Borges1,2, Gilberto de Castro3,4.   

Abstract

PURPOSE: The purpose of this study was to conduct a systematic review to assess the effect of exercise on symptoms and quality of life in lung cancer patients.
METHODS: We conducted a systematic review using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, Medline, Embase, Scopus, Web of Science, and SciELO were searched for studies published from January 1998 to January 2019. The review included all randomized controlled trials that evaluated the effect of exercise on symptoms and quality of life of lung cancer patients. Two reviewers independently assessed the quality of all the included studies using the Physiotherapy Evidence Database scale.
RESULTS: In total, ten studies (835 participants) met all inclusion criteria. Three studies investigated the effect of exercise after lung resection, whereas four studies investigated it as a pre-surgery intervention. Two studies investigated the effect of exercise in patients under systemic treatment only, and one study included patients on diverse treatment plans. Exercise protocols consisted of different combinations of strength, aerobic, and inspiratory muscle training. Two trials, including 101 participants, found significant difference in quality of life between groups, favoring the intervention group; and five trials, including 549 participants, found significant inter-group differences in isolated symptoms, also favoring the intervention group.
CONCLUSIONS: Exercise can lead to improvements of symptoms and of quality of life in lung cancer survivors. Providing resistance training combined with high-intensity interval aerobic exercise after lung resection seems to be particularly effective. Further studies are warranted to investigate exercise for patients with poor performance status.

Entities:  

Keywords:  Exercise; Lung cancer; Quality of life; Systematic review

Mesh:

Year:  2020        PMID: 32388616     DOI: 10.1007/s00520-020-05499-6

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  38 in total

1.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  D Planchard; S Popat; K Kerr; S Novello; E F Smit; C Faivre-Finn; T S Mok; M Reck; P E Van Schil; M D Hellmann; S Peters
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

Review 2.  The biology and management of non-small cell lung cancer.

Authors:  Roy S Herbst; Daniel Morgensztern; Chris Boshoff
Journal:  Nature       Date:  2018-01-24       Impact factor: 49.962

3.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P E Postmus; K M Kerr; M Oudkerk; S Senan; D A Waller; J Vansteenkiste; C Escriu; S Peters
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

4.  Early palliative care for patients with metastatic non-small-cell lung cancer.

Authors:  Jennifer S Temel; Joseph A Greer; Alona Muzikansky; Emily R Gallagher; Sonal Admane; Vicki A Jackson; Constance M Dahlin; Craig D Blinderman; Juliet Jacobsen; William F Pirl; J Andrew Billings; Thomas J Lynch
Journal:  N Engl J Med       Date:  2010-08-19       Impact factor: 91.245

Review 5.  The Exercise and Sports Science Australia position statement: Exercise medicine in cancer management.

Authors:  Sandra C Hayes; Robert U Newton; Rosalind R Spence; Daniel A Galvão
Journal:  J Sci Med Sport       Date:  2019-05-10       Impact factor: 4.319

6.  Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey.

Authors:  Daniel Morgensztern; Shean Huey Ng; Feng Gao; Ramaswamy Govindan
Journal:  J Thorac Oncol       Date:  2010-01       Impact factor: 15.609

7.  The extent of lung parenchyma resection significantly impacts long-term quality of life in patients with non-small cell lung cancer.

Authors:  Tobias Schulte; Bodo Schniewind; Peter Dohrmann; Thomas Küchler; Roland Kurdow
Journal:  Chest       Date:  2008-08-08       Impact factor: 9.410

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 9.  Impact of physical exercise in cancer survivors during and after antineoplastic treatments.

Authors:  Martina Ferioli; Giorgio Zauli; Alberto M Martelli; Marco Vitale; James A McCubrey; Simona Ultimo; Silvano Capitani; Luca M Neri
Journal:  Oncotarget       Date:  2018-02-08

10.  Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades.

Authors:  Tao Lu; Xiaodong Yang; Yiwei Huang; Mengnan Zhao; Ming Li; Ke Ma; Jiacheng Yin; Cheng Zhan; Qun Wang
Journal:  Cancer Manag Res       Date:  2019-01-21       Impact factor: 3.989

View more
  3 in total

1.  Dynamic Changes and Influencing Factors for the Quality of Life in Nursing Care after Lung Cancer Resection.

Authors:  Shuzhen Hu; Aihong Fang
Journal:  Contrast Media Mol Imaging       Date:  2022-07-31       Impact factor: 3.009

2.  Longitudinal changes in pulmonary function and patient-reported outcomes after lung cancer surgery.

Authors:  Sumin Shin; Sunga Kong; Danbee Kang; Hong Kwan Kim; Hye Yun Park; Genehee Lee; Jong Ho Cho; Young Mog Shim; Juhee Cho
Journal:  Respir Res       Date:  2022-08-30

Review 3.  Food, Nutrition, Physical Activity and Microbiota: Which Impact on Lung Cancer?

Authors:  Ersilia Nigro; Fabio Perrotta; Filippo Scialò; Vito D'Agnano; Marta Mallardo; Andrea Bianco; Aurora Daniele
Journal:  Int J Environ Res Public Health       Date:  2021-03-01       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.